79 results about "Clinical disease" patented technology

The invention discloses an adverse drug reaction event recognition method and system based on multivariate knowledge mixed retrieval enhancement, and the method comprises the steps: extracting drug entities from a to-be-recognized clinical disease course record, segmenting the disease course record, and obtaining a drug entity set and a sentence set; for each extracted drug entity, retrieving drug concept knowledge having a hyponymy relationship with the drug entity and drug adverse reaction knowledge having an adverse reaction relationship with the drug entity in a pre-constructed multivariate knowledge base; for each sentence obtained through segmentation, searching suspected adverse drug reaction events meeting a first similarity requirement and drug field text knowledge meeting a second similarity requirement in a pre-constructed multivariate knowledge base; and finally, calling a large language model, taking all the retrieved knowledge as reference knowledge, and identifying the adverse drug reaction event from the to-be-identified clinical disease course record. According to the invention, the accuracy and reliability of adverse drug reaction event identification can be improved.

The present invention relates to the technical field of dental medical treatment, and specifically discloses a method for using a CBCT (Cone Beam Computer Tomography) for automatically positioning a tooth, which comprises the following steps: S01, archiving CT data; S02, calculating AI and generating AI results; S03, entering CT reading by a client; S04, downloading and loading the CT data; S05, opening a function of a tooth lens; S06, selecting a corresponding tooth position in a tooth position list; and S07, selecting a 3D tooth rendering mode. The function of the ‘tooth lens’ is added into traditional CT reading, which is suitable for clinical disease diagnoses such as ‘tooth extraction, root canal therapy, tooth repair’ and the like in oral treatment, and doctors can precisely and quickly position the single tooth through selection for the tooth position, which facilitates more comprehensive analysis.

The invention discloses a multi-dimensional quality cross validation evaluation method and system based on medical model training, and belongs to the technical field of medical file evaluation. Constructing a pathological feature sample library and a medical record archive library based on the pathological feature description words and the medical record archives, and classifying and recording the medical record archives through the pathological feature description words; according to the incidence process of the pathological characteristics, forming an incidence state transition relation chain and configuring incidence state verification nodes; in combination with a clinical pathology state time range of the pathology state verification node, screening associated cross-pathology features to form a cross-pathology label; and updating according to a verification node sequence to obtain a disease occurrence state cross relation chain, performing multi-dimensional quality evaluation on the medical record file, and outputting an evaluation value. According to the method, the accuracy and reliability of medical file quality evaluation are improved through multi-dimensional cross validation, high-quality medical record data support is provided for medical model training, and the method is suitable for medical record quality auditing, medical data treatment and medical model training data screening scenes of medical institutions at all levels.

The application discloses a lumbar disc herniation postoperative recurrence risk prediction system based on domain offset correction, and relates to the technical field of medical data processing and clinical disease risk prediction. The system obtains the multi-modal clinical and imaging feature vectors and follow-up outcome data of a training queue and an independent verification queue, trains a central classifier to quantize and correct the multi-center data distribution difference, calculates and trims the importance weight of each training case, trains a survival analysis base learner based on the processed weight and performs stacked integration, determines a final deployment model in combination with an independent verification case queue, calls the final deployment model to perform reasoning on a target patient after lumbar disc herniation surgery, and outputs an individualized recurrence risk score, risk stratification and recurrence-free survival curve, thereby improving the robustness and reliability of the risk prediction system in a cross-center scenario, and being suitable for postoperative follow-up management of lumbar disc herniation and auxiliary clinical decision-making.

The invention discloses a herpes zoster skin lesion staging evaluation method and system based on AI image recognition, and relates to the technical field of herpes zoster skin lesion staging evaluation, and the method comprises the following steps: collecting herpes zoster skin lesion image data continuously recorded in multiple periods, synchronously embedding a time identifier in the collection process, and carrying out the time identification; recording the shooting moment, the illumination state and the shooting angle information of each frame of image in a unified manner to form an original image sequence; and based on the original image sequence, according to the progressive sequence of the time identifiers, performing adaptive sorting adjustment on the time intervals between the adjacent frames. According to the method, a stable skin lesion time evolution track is constructed through time identification and a continuous processing flow, so that staging reverse judgment caused by frame order disorder is avoided, and the continuity and reliability of herpes zoster skin lesion staging evaluation are improved; and meanwhile, color, area and texture changes are uniformly incorporated into natural time rhythm constraints, so that a staging result better conforms to a clinical disease course rule, and the safety of remote follow-up visit and intelligent evaluation is improved.

The application discloses a high-channel clinical microelectrode array intelligent brain function positioning system and method, and belongs to the fields of electronic information and clinical disease diagnosis and treatment technologies. The system comprises a microelectrode array implanted in the brain, a signal processing and transmission unit and a signal identification unit. The microelectrode array adopts a multi-channel design, can synchronously detect neural electrophysiological signals and transmitter chemical signals of different depths and directions, and has a resolution of a single cell level. The signal processing and transmission unit is responsible for signal acquisition, amplification and transmission, and applies electrical stimulation; the signal identification unit performs real-time processing on the signals through a convolutional neural network algorithm, quickly identifies target nuclei, and realizes accurate positioning. The application can realize real-time monitoring of neural cell discharges and transmitter releases at different depths and different directions, and can realize rapid and accurate target positioning with the aid of advanced intelligent algorithms, thereby providing a more reliable basis for DBS surgery.

The invention belongs to the technical field of mass spectrum ionization sources, provides a tandem mass spectrum ionization source for online detection of disease markers in tail end gas of expired gas of a human body, and aims to solve the problems of complex expired gas sampling, insufficient detection sensitivity and difficult real-time monitoring in the prior art. According to the ionization source device, real-time online expiration analysis of expired gas of a human body can be achieved, the expired gas end gas moment can be determined according to the change of the concentration of carbon dioxide in the expired gas, and therefore real-time analysis of disease markers in the expired gas end gas is achieved. According to the technical scheme, the design that double ionization sources are connected in series is adopted, and a funnel-shaped chemical ionization source is arranged at the front end and specially used for high-sensitivity detection of volatile organic compounds in exhaled air; the photoelectron ionization source is arranged at the rear end and used for monitoring the carbon dioxide concentration in real time and determining the end gas moment. According to the design, high sensitivity of organic matter detection and accurate monitoring of carbon dioxide concentration are both considered in a partitioned ionization mode. The efficient, sensitive and reliable mass spectrum ionization source device is provided for exhaled gas detection, automatic distinguishing of the front end and the tail end of exhaled gas and high-sensitivity analysis of disease markers in tail end gas can be achieved, the sampling process can be simplified, the detection efficiency can be improved, and the mass spectrum ionization source device has wide application prospects, can be suitable for various scenes and has wide application prospects. The method includes clinical disease early diagnosis, health monitoring and the like.

The application relates to a whole-body organ metabolism network analysis method, device, equipment and storage medium. The method comprises the following steps: collecting a PET image of a subject, obtaining SUV images, Ki images and TAC data according to the PET image, and collecting physiological information, clinical pathology information and daily habit information of the subject; metabolism characteristics are extracted based on the PET images, SUV images and Ki images corresponding to the region of interest; the TAC data of each organ is curve-fitted by using the PET image, and the metabolism disturbance under different organs is represented by using the fitting residual error; a whole-body organ metabolism network is constructed according to the physiological information, clinical pathology information, daily habit information, metabolism characteristics and metabolism disturbance; and the whole-body organ metabolism of the subject is analyzed through the whole-body organ metabolism network. The application avoids individual differences, can more comprehensively capture the metabolism correlation among whole-body organs of a specific disease, and is helpful for early diagnosis, accurate evaluation and individualized treatment of clinical diseases.

The invention discloses a fibroblast preparation and a preparation method and application thereof, and belongs to the technical field of biomedical engineering, and the fibroblast preparation is prepared by mixing and compounding fibroblasts, a carrier and an active substance solution. The preparation method comprises the following steps: S1, cell pretreatment; s2, preparing a cross-linked collagen fiber hydrogel; s3, preparing an active substance solution; and S4, preparing the fibroblast preparation. By pretreating fibroblasts, activating the anti-inflammatory phenotype of the fibroblasts, promoting the fibroblasts to secrete collagen, loading the cells through collagenous fiber hydrogel and adding active substances, the skin lesion is repaired, meanwhile, type II immune excessive activation is inhibited, and the clinical disease performance of eczema mice is remarkably improved. The problems of limited skin disease treatment and skin lesion repair effects caused by low cell survival rate, poor carrier biocompatibility and poor active substance synergism in the prior art are solved, and the preparation method has the potential of preparing drugs for treating skin diseases.

The invention belongs to the technical field of antiviral drugs for livestock and poultry, and discloses application of lysophosphatidylcholine and dihydromyricetin in preparation of drugs for treating or preventing porcine reproductive and respiratory syndrome virus infection. The CAS number of the lysophosphatidylcholine is 17364 to 16 to 8, and the CAS number of the dihydromyricetin is 27200 to 12 to 0. The applicant performs cell level and animal body level anti-infection research on the pharmaceutical composition, and finds that the pharmaceutical composition shows a remarkable anti-PRRSV effect in vivo and in vitro, can reduce proliferation of viruses in a pig body, reduces damage of PRRSV infection to lung tissues and organs, effectively controls adverse effects of PRRSV infection to the body, and has a remarkable anti-PRRSV effect. The clinical disease symptoms of the pigs in the PRRSV infection period can be weakened, and the porcine reproductive and respiratory syndrome can be prevented and controlled.

The Great Cerebral Vein, or Vein of Galen is comprised of a unique structure having a location which both implicates it in various clinical conditions, and can be treated by systems which, for example, go around corners of the Transverse and Straight sinuses for minimally invasive therapy embedded in the Vein of Galen the present inventions constitute progress in science and the useful arts worthy of protection as US Letters patent as novel.

The application discloses a nanobody targeting Claudin 18.2 and an application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of the nanobody in the prior art, the application provides a nanobody targeting Claudin 18.2, wherein the amino acid sequence of the nanobody is shown as SEQ ID NO. 1; the nanobody has strong affinity to 293T-Claudin 18.2 positive cells and can be combined with the Claudin 18.2 protein expressed on the cell surface. The nanobody targeting Claudin 18.2 provided by the application can be prepared by large-scale expression of an in-vitro engineering bacterium, can be applied to preparation of a protein detection antibody or a therapeutic antibody, can be used for in-vitro and in-vivo detection of tumor tissues expressing Claudin 18.2, and has important commercial value in clinical disease diagnosis and treatment.

The application discloses a nanobody targeting mesothelin and application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of nanobodies in the prior art, the application provides a nanobody targeting mesothelin, wherein the nanobody targeting mesothelin comprises CDR1 as shown in SEQ ID NO. 1, CDR2 as shown in SEQ ID NO. 2 and CDR3 as shown in SEQ ID NO. 3. The nanobody targeting mesothelin has strong binding force with cells overexpressing mesothelin. It can be seen that the nanobody targeting mesothelin can bind to mesothelin protein expressed on the surface of cells, and can be applied to preparation of a protein detection antibody or a therapeutic antibody, and has important commercial value in clinical disease diagnosis and treatment.

The invention discloses a biological age assessment method and system based on full life cycle DNA methylation and application, and belongs to the technical field of bioinformatics. The method comprises the following steps: firstly, carrying out quality control and standardization treatment on obtained original DNA methylation data; then, screening differential methylation sites significantly related to calendar age as features; then, by taking calendar age as a target variable, constructing a regression model by adopting a LightGBM gradient lifting framework to obtain a methylated clock model; then, predicting the DNA methylation age of the individual by using the model, and calculating an epigenetic age acceleration value based on the deviation between the DNA methylation age and the calendar age; and finally, carrying out correlation analysis on the age acceleration value and health or physiological indexes of different life stages, so as to evaluate the biological aging state of the individual and predict related health risks. The method covers the whole life cycle, is suitable for Chinese population, and can provide an effective tool for clinical disease risk prediction, health management and anti-aging intervention effect evaluation.

This invention discloses a conductive hydrogel, its preparation method, and its applications. The conductive hydrogel's raw materials include hydroxypropyl cellulose, hyaluronic acid, acrylamide, and a conductive agent; the conductive agent includes at least one selected from lithium chloride, potassium chloride, sodium chloride, sodium sulfate, and potassium sulfate. This conductive hydrogel utilizes the liquid-phase transition characteristics of hydroxypropyl cellulose, combined with acrylamide, hyaluronic acid, and lithium chloride to achieve respiratory and body temperature monitoring. This conductive hydrogel exhibits good conductivity and can detect different types of respiration, providing valuable monitoring for the monitoring and development of clinical diseases. Simultaneously, the synergistic effect of the combined hyaluronic acid, acrylamide, and lithium chloride adjusts the lower critical dissolution temperature of hydroxypropyl cellulose to 37°C, causing the hydrogel to change from transparent to opaque at 37°C, enabling real-time temperature and respiratory monitoring for febrile patients in clinical settings.

Provided are a double-stranded ribonucleic acid for inhibiting INHBE gene expression, a double-stranded ribonucleic acid modifier, a double-stranded ribonucleic acid conjugate, a prodrug, a pharmaceutical composition and the use, and a method for inhibiting the INHBE gene expression in a cell. The double-stranded ribonucleic acid and the modifier thereof, the conjugate thereof, and the prodrug thereof can bind in a cell to form an RNA-induced silencing complex (RISC), which cleaves mRNA transcribed from an INHBE gene, thereby efficiently and specifically inhibiting the expression of the INHBE gene. The present invention is used for treating diseases mediated by the INHBE gene, and thus has important application prospects in clinical disease treatment.

Provided is a method for constructing a humanized FKBP8 gene knock-in animal model, comprising: (1) constructing a targeting vector for humanized FKBP8 gene knock-in, and transfecting the targeting vector, Cas9, and sgRNA into fertilized eggs of donor animals; (2) transplanting surviving fertilized egg cells into the oviduct of pseudopregnant animals to obtain F0 generation animals and identifying the F0 generation animals, wherein animals showing positive homologous recombination are chimeric animals; and (3) mating the chimeric animals with wild-type animals to obtain F1 generation animals and performing identification, wherein F1 animals showing positive homologous recombination are humanized FKBP8 knock-in animals. In the construction method, an FKBP8 gene sequence in a donor animal is substituted by a human FKBP8 gene sequence, so as to achieve the purpose of humanizing the FKBP8 gene in the donor animal, thus successfully establishing a humanized FKBP8 gene knock-in animal model, so that screening for drugs targeting the FKBP8 gene and a product thereof in the animal model, or studying the pathogenesis and treatment mechanisms of the FKBP8 gene and the product thereof in related clinical diseases can be realized.

A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.

The invention discloses a bone defect clinical disease risk prediction method and system based on an intelligent chip, and the method comprises the steps: constructing a training data set containing a bone defect type, an external feature type, physiological information and a bone volume reduction rate, and distinguishing a normal state or an abnormal state according to whether a patient is accompanied with a disease affecting healing or not. Training a random forest model and a time sequence convolutional network model for a normal state and an abnormal state respectively by adopting a hybrid modeling strategy, and burning a normal / abnormal channel risk prediction model to an intelligent chip; the intelligent chip collects patient data, calculates the bone volume reduction rate, calls a corresponding model to predict future changes, and finally achieves dynamic risk early warning by comparing the deviation between a preset risk threshold value and a real-time monitoring value. According to the invention, the corresponding risk prediction model is selected based on the actual condition of the patient, and accurate and real-time risk prediction and monitoring of the bone defect healing process are realized.

This invention discloses a system for predicting the risk of recurrence after lumbar disc herniation surgery based on domain offset correction, relating to the fields of medical data processing and clinical disease risk prediction technology. The system acquires multimodal clinical and imaging feature vectors and follow-up outcome data from training and independent validation cohorts. It trains a center classifier to quantify and correct for differences in multi-center data distribution, calculates and normalizes the importance weights of each training case, trains a survival analysis base learner based on the processed weights, and performs stacking and ensemble integration. The final deployment model is determined by combining the independent validation case cohort. The final deployment model is then used to infer the risk of recurrence in target patients after lumbar disc herniation surgery, outputting individualized recurrence risk scores, risk stratification, and recurrence-free survival curves. This improves the robustness and reliability of the risk prediction system in cross-center scenarios and is suitable for follow-up management and clinical decision support after lumbar disc herniation surgery.

The invention relates to the technical field of biological detection, and discloses a method for detecting abnormal sugar chain glycoprotein, which comprises the following steps: by taking lectin modified magnetic nanoparticles as a capture probe, constructing a double-recognition system by combining a fluorescently-labeled sugar chain recognition antibody; the accurate quantification of the abnormal sugar chain glycoprotein is realized through magnetic separation and enrichment, fluorescence signal amplification and fluorescence spectrophotometry detection. The method comprises the steps of capture probe preparation, sample pretreatment, targeted capture and magnetic separation, fluorescence labeling, signal detection and result analysis. The detection limit can reach 0.05 ng / mL, the recovery rate is high, normal sugar chain glycoprotein and abnormal sugar chain glycoprotein can be effectively distinguished, and the method has the advantages of being high in specificity, high in sensitivity, easy and convenient to operate, rapid in detection and the like, is suitable for clinical disease screening, prognosis monitoring and batch detection of abnormal sugar chain glycoprotein in biological samples, and has wide application prospects.

The invention belongs to the technical field of biology, and particularly relates to construction of a pE248R protein 103 and 240 site conditional point mutation deletion strain and application of the strain as a vaccine. The method comprises the following steps: firstly, simultaneously mutating the 103 and 240 amino acid lysine of an African swine fever virus pE248R protein into arginine to construct a recombinant African swine fever virus strain; the average level of a p30 antibody in an animal immunized by the recombinant African swine fever virus strain exceeds 40% from the tenth day and the eleventh day respectively, animal death does not occur after attack of toxic substances, the recombinant African swine fever virus strain has good safety, and after attack of a parent ASFV, continuous increase of the p30 antibody level shows that the recombinant African swine fever virus strain can resist attack of a virulent parent ASFV, and clinical disease symptoms do not occur.

The invention relates to a method for determining kininogenase and a used kit. On one hand, the invention relates to a kit for determining the content of kininogenase in human plasma, the kit comprises a test solution for testing, an antigen standard substance, a capture antibody, an enzyme-labeled antibody and a test method description file which are separately packaged by containers, and the test solution comprises PBS, PBST, a washing solution, a confining solution, a sample diluent, a stop solution, a coating buffer solution, a color developing solution A and a color developing solution B. The invention also relates to a method for determining the content of kininogenase in human plasma by using the kit. According to the kit and the method provided by the invention, the amount of endogenous kininogenase or exogenous kininogenase in a human body can be accurately and effectively measured, and a beneficial tool is provided for diagnosis and treatment of clinical diseases.

The invention discloses a multiplex fluorescence quantitative detection method for simultaneously detecting four influenza A virus subtypes, a primer composition used by the multiplex fluorescence quantitative detection method and application of the primer composition. The invention belongs to the technical field of biological detection, and particularly relates to a multiplex fluorescent quantitative detection method for simultaneously detecting four influenza A virus subtypes, a primer composition used by the multiplex fluorescent quantitative detection method and application of the primer composition. The primer composition for detecting the four influenza A virus subtypes is composed of a primer probe group A, a primer probe group B, a primer probe group C and a primer probe group D, and the specific nucleotide sequences are sequence 1-sequence 12. The primer probe composition has the advantages of being high in specificity, sensitivity, repeatability and reproducibility, easy to operate and the like, the detection speed can be increased, the detection cost can be saved, and high application value is provided for influenza A virus screening and clinical disease diagnosis.

The application relates to a nanobody targeting human epidermal growth factor receptor-2 and an application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of the nanobody in the prior art, the application provides a nanobody targeting human epidermal growth factor receptor-2, wherein the amino acid sequence of the nanobody targeting human epidermal growth factor receptor-2 is shown in SEQ ID NO. 1. The nanobody targeting human epidermal growth factor receptor-2 provided by the application can be combined with human epidermal growth factor receptor-2 protein expressed on the surface of natural cells, can be prepared by being expressed in a large amount by an in-vitro engineering bacterium, can be applied to the preparation of a protein detection antibody or a therapeutic antibody, can be used for in-vitro and in-vivo detection of tumor tissues expressing human epidermal growth factor receptor-2, and has important commercial value in clinical disease diagnosis and treatment.

The invention discloses a multiplex fluorescent quantitative PCR (Polymerase Chain Reaction) detection reagent for synchronously detecting four DNA (Deoxyribose Nucleic Acid) viruses related to infectious infertility. The detection reagent comprises specific primers and probes aiming at human microviruses, adenoviruses, polyoma viruses and adeno-associated viruses; the multiple fluorescence detection method used in the invention not only can synchronously detect four infectious DNA viruses in a single reaction tube, but also can simultaneously measure the load of the viruses, and has great value for researching infectious clinical diseases. The reagent disclosed by the invention has the characteristics of strong specificity, high sensitivity, good stability, simplicity in operation, less time consumption and the like, and can greatly improve the detection efficiency and reduce the detection cost when the method is used for performing large-scale clinical screening on the infection of the four viruses; meanwhile, the detection result can also provide important reference for formulating an individualized treatment scheme, so that the kit has important clinical application value and social significance for realizing symptomatic medication and improving the treatment effect.

A double-stranded ribonucleic acid for inhibiting GPR146 gene expression, a conjugate, and use. The double-stranded ribonucleic acid can bind in cells to form an RNA-induced silencing complex (RISC), which cleaves mRNA transcribed by a GPR146 gene. Therefore, the double-stranded ribonucleic acid can selectively and efficiently inhibit the GPR146 gene expression and thereby be used in the treatment of diseases mediated by the GPR146 gene, demonstrating significant application prospects in disease treatment in clinic.

The invention belongs to the technical field of biology, and particularly relates to construction and application of a recombinant African swine fever virus strain. The method comprises the following steps: firstly, simultaneously mutating 103-site and 240-site amino acid lysine of an African swine fever virus pE248R protein into arginine, and carrying out SIM (Subscriber Identity Module) mutation on the pE248R protein to construct a recombinant African swine fever virus strain; the average level of a p30 antibody in an animal immunized by the recombinant African swine fever virus strain exceeds 40% from the tenth day and the eleventh day, animal death does not occur after challenge, the recombinant African swine fever virus strain has good safety, and after ASFV immunization, the level of the p30 antibody continuously rises and the immune protection rate is 100%, which indicates that the recombinant African swine fever virus strain can resist attack of virulent parent ASFV, and has good application prospects. And clinical disease symptoms do not appear.

The application discloses a nano antibody targeting Nectin-4 and application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of the nano antibody in the prior art, the application provides the nano antibody targeting Nectin-4, wherein the nano antibody targeting Nectin-4 comprises CDR1 shown as SEQ ID NO. 1, CDR2 shown as SEQ ID NO. 2 and CDR3 shown as SEQ ID NO. 3. The flow cytometry and western detection results show that the nano antibody targeting Nectin-4 provided by the application can be specifically combined with Nectin-4 protein expressed on the cell surface; the nano antibody can be applied to preparation of a protein detection antibody or a therapeutic antibody, and can be used for in-vivo and in-vitro detection of tumor tissues with Nectin-4 expression, and has important commercial value in clinical disease diagnosis.

In one aspect, the disclosure relates to compounds that behave as molecular glue degraders (MGDs) and methods of making and using same. In various aspects, the disclosed compounds are useful for modulating PPIL4 activity through targeted degradation. In various aspects, the compounds are useful for treating medulloblastoma and / or acute lymphoblastic leukemia (ALL). In further aspects, the present disclosure relates to methods of making the disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating various clinical conditions and disorders using the same, such as T-cell acute lymphoblastic leukemia. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.